Evidence map›Paper›PMID 28739029›Full record

ReviewCytokine & growth factor reviews2017

IL-9 and Th9 cells in health and diseases-From tolerance to immunopathology.

Junhui Li, Shuqiu Chen, Xiang Xiao, Yong Zhao, Wenjun Ding, Xian C Li

Abstract readReview
In one paragraph

Review in Cytokine & growth factor reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Microbiota-derived HNature communications · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Frontiers in pharmacology · 2024
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Intervertebral disc degeneration and inflammatory microenvironment: expression, pathology, and therapeutic strategies.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Junhui LiImmunobiology and Transplant Science Center, Houston Methodist Hospital and Houston Methodist Research Institute, Texas Medical Center, Houston, TX, United States; Center for Organ Transplantation, The 3rd Xiangya Hospital, Central South University, Changsha, Hunan, China.
Shuqiu ChenImmunobiology and Transplant Science Center, Houston Methodist Hospital and Houston Methodist Research Institute, Texas Medical Center, Houston, TX, United States.
Xiang XiaoImmunobiology and Transplant Science Center, Houston Methodist Hospital and Houston Methodist Research Institute, Texas Medical Center, Houston, TX, United States.
Yong ZhaoInstitute of Zoology, Chinese Academy of Sciences, Beijing, China.
Wenjun DingUniversity of Chinese Academy of Sciences, Beijing, China.
Xian C LiImmunobiology and Transplant Science Center, Houston Methodist Hospital and Houston Methodist Research Institute, Texas Medical Center, Houston, TX, United States. Electronic address: xcli@houstonmethodist.org.

Funding

Control of Treg exhaustion by OX40R01AI106200 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI LI, XIAN CHANG · 2014 to 2025
$4.2M
NIAID NIH HHS R01 AI106200
6 · The paper itself

Abstract

CD4+ T cells have the capacity to differentiate into various T helper (Th) cell subsets after activation, and by acquiring distinct cytokine profiles and effector functions, they regulate the nature as well as the outcomes of immune responses. Th9 cells are a relatively new member in the Th cell family. The signature cytokine for Th9 cells is IL-9, a cytokine in the IL-2Rγc-chain family. Over the past few years, there has been an explosion of knowledge on the roles of Th9 cells in immunity and immunopathology, but the exact mechanisms in the control of Th9 cells remain poorly defined. This apparent paradox presents both challenges and opportunities. Here we review recent advances in our understanding of the fundamental biology of IL-9 and Th9 cells, highlighting the challenges and unanswered questions in the field. We also discuss potential opportunities in targeting Th9 cells for therapeutic purposes in the clinic.

Indexed as

Immune ToleranceAnimalsCell DifferentiationHumansInterleukin-4Interleukin-9MiceSignal TransductionT-Lymphocytes, Helper-InducerTransforming Growth Factor beta1IL4 protein, humanInterleukin-4Interleukin-9Transforming Growth Factor beta1Immunity and immunopathologyTh9Therapeutic purposesTranscription mechanism

Identifiers

PMID28739029
PMCPMC5632571

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.